Novartis Ag (NVS) EBITDA (2009 - 2026)
Novartis Ag (NVS) posted EBITDA of $4.8 billion for Q2 2026, down 2.34% sequentially from $4.9 billion in Q2 2025, and down 2.34% YoY from $4.9 billion in Q2 2025.
Novartis Ag (NVS) EBITDA (2009 - 2026) Analysis & Trends
Novartis Ag has reported EBITDA for 18 years, with the latest figure at $4.8 billion in Q2 2026.
- Quarterly EBITDA fell 2.34% year-over-year to $4.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $43.1 billion (down 1.54% YoY) and the FY2025 annual result came in at $17.6 billion, up 21.31% from the prior year.
- EBITDA slipped to $4.8 billion in Q2 2026 per NVS's latest filing, from $4.9 billion in the prior quarter.
- Over five years, EBITDA peaked at $34000.7 billion in Q1 2022 and troughed at $673.0 million in Q3 2022.
- A 5-year average of $3553.3 billion and a median of $4.9 billion in 2025 frame the typical range for EBITDA.
- The sharpest annual moves came in 2023 and 2024: EBITDA sank 85.29% in 2023, then jumped 442.71% in 2024.
- Over 5 years, EBITDA stood at $30.2 billion in 2022, then tumbled by 82.04% to $5.4 billion in 2023, then surged by 442.71% to $29.4 billion in 2024, then sank by 83.48% to $4.9 billion in 2025, then decreased by 2.34% to $4.8 billion in 2026.
- According to Business Quant data, EBITDA over the past three periods registered $4.8 billion, $4.9 billion, and $29.4 billion for Q2 2026, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 3.16 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 3.51 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -10.39 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 4.27 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 645.35 Mn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 16.77 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.75 Bn |
| Jun 30, 2025 | 4.86 Bn |
| Dec 31, 2024 | 29.44 Bn |
| Jun 30, 2024 | 4.01 Bn |
| Dec 31, 2023 | 5.43 Bn |
| Jun 30, 2023 | 2.81 Bn |
| Mar 31, 2023 | 5,000.76 Bn |
| Dec 31, 2022 | 30.20 Bn |
| Sep 30, 2022 | 673.00 Mn |
| Jun 30, 2022 | 2.23 Bn |
| Mar 31, 2022 | 34,000.72 Bn |
| Dec 31, 2021 | 12.05 Bn |
| Sep 30, 2021 | 725.00 Mn |
| Jun 30, 2021 | 3.48 Bn |
| Mar 31, 2021 | 14,000.72 Bn |
| Dec 31, 2020 | 11.38 Bn |
| Sep 30, 2020 | 18,000.70 Bn |
| Jun 30, 2020 | 2.35 Bn |
| Mar 31, 2020 | -45.00 Mn |
| Jun 30, 2019 | 2.66 Bn |